Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 9/20 | 0.53 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | PRLHR | P49683 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262661 | 0.94 | NPY2R (0.51) | NPY2RNPY1RNPY4RNPY5RKLK5 | |
| SCHEMBL13197591 | 0.80 | AGTR2 (0.53) | NPY2RKLK5CTNNB1AGTR2AGTR1 | |
| SCHEMBL18872896 | 0.74 | AGTR1 (0.68) | NPY2RNPY1RNPY4RNPY5RAGTR2 | |
| SCHEMBL18872894 | 0.74 | AGTR1 (0.68) | NPY2RNPY1RNPY4RNPY5RAGTR2 | |
| Trv-120027 SCHEMBL29382211 | 0.73 | AGTR1 (0.73) | NPY2RNPY1RNPY4RNPY5RAGTR2 | |
| Angiotensin-Ii SCHEMBL29362121 | 0.73 | AGTR2 (0.76) | NPY2RNPY1RNPY4RNPY5RAGTR2 | |
| Angiotensin Ii SCHEMBL2183118 | 0.72 | AGTR2 (0.83) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL13232382 | 0.72 | AGTR2 (0.84) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL2566771 | 0.72 | AGTR2 (0.84) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL1189 | 0.72 | AGTR2 (0.84) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | AGTR1, AGTR2, AGT | NPY2R 666/4885NPY1R 391/4885NPY4R 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.